Preparation and Characterization of A Nanoliposomal Vaccine of pcLACK Candidate Against Cutaneous Leishmaniasis.

Leishmania major encapsulation. immunity nanoliposomal pcLACK vaccine

Journal

Infectious disorders drug targets
ISSN: 2212-3989
Titre abrégé: Infect Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269158

Informations de publication

Date de publication:
2021
Historique:
received: 23 02 2020
revised: 01 07 2020
accepted: 11 08 2020
pubmed: 7 10 2020
medline: 16 10 2021
entrez: 6 10 2020
Statut: ppublish

Résumé

Leishmaniasis is a public health problem and endemic in countries of the tropics and subtropics. An ongoing project with naked LACK (Leishmania homolog of receptors for activated C-kinase) demonstrated that this case of the gene is entirely susceptible to immune response and it does enter the cells effectively. This study aimed at developing a procedure to prepare a type of lipid nanoparticles overloaded with plasmid LACK (pcLACK) for usage as Leishmania major (L. major) nanoliposomal vaccine. The single-gene expression plasmid of pcLACK was encoded in the LACK antigen. Nanoparticles were set up by thin film procedure using cationic lipids 1, 2-Dioleoyl- 3-Trimethylammonium propane (DOTAP), 1, 2-Dioleoyl-snGlycero-3-Phosphoethanolamine (DOPE), and cholesterol in a molar proportion of 2:1:1 molar ratio. Using dynamic light scattering, the particle diameters of empty and loaded lipoplexes were measured in triplicate. The zeta-potential (ζ) was measured with the same instrument using the zeta potential mode as the average of 20 measurements by diluting the particles into a low salt buffer. The results of the sustainability studies of Liposome-pcLACK formulation showed that there were no significant physical changes up to the 30th day of stability study at the storage condition of 4°C. However, there were significant changes in the formulation content during storage at 25°C for 30 days (204.2±0.90 at Day 30 compared with 207.2±0.26 nm at Day 0). It was observed that the prepared nanoliposomal formulation had more stability under refrigeration. Immunostimulatory cationic lipids bearing a pcLACK encapsulation could serve as an effective delivery system.

Sections du résumé

BACKGROUND BACKGROUND
Leishmaniasis is a public health problem and endemic in countries of the tropics and subtropics. An ongoing project with naked LACK (Leishmania homolog of receptors for activated C-kinase) demonstrated that this case of the gene is entirely susceptible to immune response and it does enter the cells effectively. This study aimed at developing a procedure to prepare a type of lipid nanoparticles overloaded with plasmid LACK (pcLACK) for usage as Leishmania major (L. major) nanoliposomal vaccine.
MATERIALS AND METHODS METHODS
The single-gene expression plasmid of pcLACK was encoded in the LACK antigen. Nanoparticles were set up by thin film procedure using cationic lipids 1, 2-Dioleoyl- 3-Trimethylammonium propane (DOTAP), 1, 2-Dioleoyl-snGlycero-3-Phosphoethanolamine (DOPE), and cholesterol in a molar proportion of 2:1:1 molar ratio. Using dynamic light scattering, the particle diameters of empty and loaded lipoplexes were measured in triplicate. The zeta-potential (ζ) was measured with the same instrument using the zeta potential mode as the average of 20 measurements by diluting the particles into a low salt buffer.
RESULTS RESULTS
The results of the sustainability studies of Liposome-pcLACK formulation showed that there were no significant physical changes up to the 30th day of stability study at the storage condition of 4°C. However, there were significant changes in the formulation content during storage at 25°C for 30 days (204.2±0.90 at Day 30 compared with 207.2±0.26 nm at Day 0). It was observed that the prepared nanoliposomal formulation had more stability under refrigeration.
CONCLUSION CONCLUSIONS
Immunostimulatory cationic lipids bearing a pcLACK encapsulation could serve as an effective delivery system.

Identifiants

pubmed: 33019941
pii: IDDT-EPUB-110443
doi: 10.2174/1871526520666201005141159
doi:

Substances chimiques

Cations 0
Lipids 0
Liposomes 0
Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-533

Subventions

Organisme : Mazandaran University of Medical Sciences
ID : 8015

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Hajar Ziaei Hezarjaribi (HZ)

Toxoplasmosis Research Center, Iranian National Registry Center for Toxoplasmosis(INRCT), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Masoud Soosaraei (M)

Toxoplasmosis Research Center, Iranian National Registry Center for Toxoplasmosis(INRCT), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Mahdi Fakhar (M)

Toxoplasmosis Research Center, Iranian National Registry Center for Toxoplasmosis(INRCT), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Javad Akhtari (J)

Toxoplasmosis Research Center, Iranian National Registry Center for Toxoplasmosis(INRCT), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Alireza Rafiei (A)

Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Oghol Niaz Jorjani (ON)

Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH